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Abstract
Introduction Sulfur compounds isolated from garlic exert anti-
inflammatory properties. We recently isolated thiacremonone, a
novel sulfur compound from garlic. Here, we investigated the
anti-inflammatory and arthritis properties of thiacremonone
through inhibition of NF-κB since NF-κB is known to be a target
molecule of sulfur compounds and an implicated transcription
factor regulating inflammatory response genes.
Methods The anti-inflammatory and arthritis effects of
thiacremone in in vivo were investigated in 12-O-
tetradecanoylphorbol-13-acetate-induced ear edema,
carrageenan and mycobacterium butyricum-induced
inflammatory and arthritis models. Lipopolysaccharide-induced
nitric oxide (NO) production was determined by Griess method.
The DNA binding activity of NF-κB was investigated by
electrophoretic mobility shift assay. NF-κB and inducible nitric
oxide synthetase (iNOS) transcriptional activity was determined
by luciferase assay. Expression of iNOS and cyclooxygenase-2
(COX-2) was determined by western blot.
Results The results showed that topical application of
thiacremonone (1 or 2 μg/ear) suppressed the 12-O-
tetradecanoylphorbol-13-acetate-induced (1 μg/ear) ear
edema. Thiacremonone (1-10 mg/kg) administered directly into
the plantar surface of hind paw also suppressed the
carrageenan (1.5 mg/paw) and mycobacterium butyricum (2
mg/paw)-induced inflammatory and arthritic responses as well
as expression of iNOS and COX-2, in addition to NF-κB DNA-
binding activity. In further in vitro study, thiacremonone (2.5-10
μg/ml) inhibited lipopolysaccharide (LPS, 1 μg/ml)-induced
nitric oxide (NO) production, and NF-κB transcriptional and
DNA binding activity in a dose dependent manner. The inhibition
of NO by thiacremonone was consistent with the inhibitory
effect on LPS-induced inducible nitric oxide synthase (iNOS)
and COX-2 expression, as well as iNOS transcriptional activity.
Moreover, thiacremonone inhibited LPS-induced p50 and p65
nuclear translocation, resulting in an inhibition of the DNA
binding activity of the NF-κB. These inhibitory effects on NF-κB
activity and NO generation were suppressed by reducing
agents dithiothreitol (DTT) and glutathione, and were abrogated
in p50 (C62S)-mutant cells, suggesting that the sulfhydryl group
of NF-κB molecules may be a target of thiacremonone.
Conclusions The present results suggested that
thiacremonone exerted its anti-inflammatory and anti-arthritic
properties through the inhibition of NF-κB activation via
interaction with the sulfhydryl group of NF-κB molecules, and
thus could be a useful agent for the treatment of inflammatory
and arthritic diseases.
AIA: adjuvant-induced arthritis; CCK-8: cell counting kit-8; CO2: carbon dioxide; COX-2: cyclooxygenase-2; DMEM: Dulbecco's modified eagle 
medium; DTT: dithiothreitol; ECL: enhanced chemiluminescence; EMSA: electromobility shift assay; GFP: green fluorescent protein; ICR: Institute of 
Cancer Research; IκB: inhibitory κB; IFN: interferon; IKK: inhibitory κB kinase; IL: interleukin; iNOS: inducible nitric oxide synthetase; LPS: lipopoly-
saccharide; MMP: matrix metalloproteinases; NF: nuclear factor; NO: nitric oxide; PBS: phosphate-buffered saline; SD: Sprague-Dawley; TNF: tumor 
necrosis factor; TPA: 12-O-tetradecanoylphorbol-13-acetate.Arthritis Research & Therapy    Vol 11 No 5    Ban et al.
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Introduction
Garlic has been used in traditional medicine as a food compo-
nent to prevent the development of cancer and cardiovascular
diseases, by modifying risk factors such as hypertension, high
blood cholesterol and thrombosis, and preventing other
chronic diseases associated with aging [1-4]. These pharma-
cological effects of garlic are attributed to the presence of
pharmacologically active sulfur compounds including diallyl
sulfide, diallyl disulfide, allicin, and dipropyl sulfide. These
compounds have been known to increase the activity of
enzymes involved in the metabolism of carcinogens [5], and
have anti-oxidative activities [6] as well as anti-inflammatory
effects in vitro and in vivo [7-13]. Despite their widespread
medicinal use and anti-inflammatory effects, little is known
about the cellular and molecular mechanisms of the compo-
nents of garlic.
Nuclear factor (NF)-κB is a family of transcription factors that
includes RelA (p65), NF-κB1 (p50 and p105), NF-κB2 (p52
and p100), c-Rel, and RelB. These transcription factors are
sequestered in the cytoplasm by inhibitory (I) κBs, which pre-
vent NF-κB activation, and inhibit nuclear accumulation. The
degradation of IκBs facilitates the migration of NF-κB into the
nucleus, where they typically form homodimers or heterodim-
ers that bind to the promoters of many inflammatory response
genes and activate transcription [14,15]. Targeted disruption
of the p50 subunit of NF-κB reduces ventricular rupture as
well as improving cardiac function and survival after myocar-
dial infarction, a proinflammatory disease [16,17]. It is also well
appreciated that p50 homodimers are important in the inflam-
matory cytokine genes, and that the ratio of p50 relative to the
other Rel (p65) family members in the nucleus is likely to be a
determining factor for gene expression of inflammation. NF-κB
regulates host inflammatory and immune response properties
by increasing the expression of specific cellular genes [18].
These include the transcription of various inflammatory
cytokines, such as IL-1, IL-2, IL-6, IL-8 and TNF-α [19], as well
as genes encoding cyclooxygenase-2 (COX-2) and iNOS. As
a result, inhibition of signal pathways leading to inactivation of
NF-κB is now widely recognized as a valid strategy combating
autoimmune, inflammatory, and osteolytic diseases [20].
Several studies have shown that inhibitors of NF-κB may be
useful in the treatment of inflammatory diseases including
arthritis [21-23]. Anti-inflammatory drugs have also been dem-
onstrated to inhibit the NF-κB pathway [24-26]. We recently
also found that inhibition of NF-κB can ameliorate inflamma-
tory responses, and arthritis [27-30]. Several recent investiga-
tions have shown that sulfur compounds can effectively
interfere with the NF-κB pathway [31-33]. In a series of phar-
macological studies of sulfur compound in garlic, we found
that the antioxidant properties of garlic-water extract is
increased by a raise in the heating temperature of the extract.
We isolated and identified thiacremonone, a novel and major
sulfur compund (0.3%) in garlic, and found that it has higher
anti-oxidant properties compared with other sulfur compounds
[34,35]. We also reported an inhibitory effect of thiacre-
monone on NF-κB activity in colon carcinoma cell lines, in par-
allel with the inhibitory effect of colon cell growth and
induction of apoptosis [15]. In this study, we investigated
whether thiacremonone exerted anti-inflammatory and arthritis
effects through the inhibition of NF-κB activity.
Materials and methods
Chemicals
Characterization of a novel sulfur compound isolated from gar-
lic (named thiacremonone) has been described elsewhere
[15,34]. Its structure is shown in Figure 1. Thiacremonone was
resolved in 0.01% dimethyl sulfoxide, and treated at sample
sizes of 2.5, 5 and 10 μg/ml in culture cells.
Cell culture
RAW 264.7, a mouse macrophage-like cell line and THP-1, a
human monocytic cell line, were obtained from the American
Type Culture Collection (Cryosite, Lane Cove, NSW, Aus-
tralia). DMEM, RPMI, penicillin, streptomycin, and fetal bovine
serum were purchased from Gibco Life Technologies (Rock-
ville, MD, USA). RAW 264.7 cells were grown in DMEM with
10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37°C in 5% carbon dioxide (CO2) humidified
air. THP-1 cells were grown in RPMI with 10% fetal bovine
serum, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin, and
100 μg/ml streptomycin at 37°C in 5% CO2 humidified air.
Cell viability assay
RAW 264.7 cells were plated at a density of 104 cells/well in
96-well plates. To determine the appropriate dose that is not
cytotoxic to the cells, the cytotoxic effect was evaluated in the
cells cultured for 24 hours using the cell counting kit-8 assay
Figure 1
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according to the manufacturer's instructions (Dojindo, Gaith-
ersburg, MD, USA). Briefly, 10 μl of the cell counting kit-8
(CCK-8) solution was added to cell culture, and incubated for
a further 24 hours. The resulting color was assayed at 450 nM
using a microplate absorbance reader (Sunrise, Tecan, Swit-
zerland). Each assay was carried out in triplicate.
Nitrite assay
RAW 264.7 cells were plated at 2 × 104 cells/well in 96-well
plate and then incubated with or without lipopolysaccharide
(LPS; 1 μg/ml) in the absence or presence of various concen-
trations of thiacremonone for 24 hours. The nitrite accumula-
tion in the supernatant was assessed by Griess reaction [36].
Each 50 μl of culture supernatant was mixed with an equal vol-
ume of Griess reagent (0.1% N-(1-naphthyl)-ethylenediamine,
1% sulfanilamide in 5% phophoric acid) and incubated at
room temperature for 10 minutes. The absorbance at 550 nm
was measured in an automated microplate reader, and a series
of known concentrations of sodium nitrite was used as a
standard.
Electromobility shift assay
Electromobility shift assay (EMSA) was performed as
described previously [15]. Briefly, 1 × 106  cells/ml was
washed twice with 1 × PBS, followed by the addition of 1 ml
of PBS, and the cells were scraped into a cold Eppendorf
tube. Cells were spun down at 15,000 g for one minutes, and
the resulting supernatant was removed. Solution A (50 mM
HEPES, pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol, 0.1 μg/ml phenylmethylsulfonyl fluoride, 1 μg/ml
pepstatin A, 1 μg/ml leupeptin, 10 μg/ml soybean trypsin
inhibitor, 10 μg/ml aprotinin, and 0.5% Nonidet P-40) was
added to the pellet in a 2:1 ratio (v/v) and incubated on ice for
10 minutes. Solution C (solution A + 10% glycerol and 400
mM KCl) was added to the pellet in a 2:1 ratio (v/v) and vor-
texed on ice for 20 minutes. The cells were centrifuged at
15,000 g for seven minutes, and the resulting nuclear extract
supernatant was collected in a chilled Eppendorf tube. Con-
sensus oligonucleotides were end-labeled using T4 polynucle-
otide kinase and (γ -32P) ATP for 10 minutes at 37°C. Gel shift
reactions were assembled and allowed to incubate at room
temperature for 10 minutes followed by the addition of 1 μl
(50,000 to 200,000 cpm) of 32P-labeled oligonucleotide and
another 20 minutes of incubation at room temperature. Subse-
quently 1 μl of gel loading buffer was added to each reaction
and loaded onto a 4% nondenaturing gel and electrophoresed
until the dye was 75% of the way down the gel. The gel was
dried at 80°C for one hour and exposed to film overnight at
70°C. The relative density of the protein bands was scanned
by densitometry using MyImage (SLB, Seoul, Korea), and
quantified by Labworks 4.0 software (UVP Inc., Upland, CA,
USA). The relative density of the DNA-protein binding bands
was scanned by densitometry using MyImage (SLB, Seoul,
Korea), and quantified by Labworks 4.0 software (UVP Inc,
Upland, CA, USA).
Transfection and assay of luciferase activity
RAW 264.7 cells (5 × 106 cells) were plated in 24-well plates
and transiently transfected with pNF-κB-Luc plasmid (5 × NF-
κB; Stratagene, La Jolla, CA, USA) or iNOS-luciferase
reporter plasmid [37] or p50 (C62S) mutant plasmids using a
mixture of plasmid and lipofectAMINE PLUS in OPTI-MEN
according to manufacturer's specification (Invitrogen,
Carlsbad, CA, USA). Cells were transiently co-transfected
with pEGFP-C1 vector (Clontech, Palo Alto, CA, USA) with
WelFect-EX™  PLUS  transfection reagent (WelGENE Inc.,
Daegu, Korea) according to the manufacturer's instructions.
After 24 hours transfection, expression of green fluorescent
protein (GFP) was detected by fluorescence microscopy
(DAS microscope: Leica Microsystems, Inc., Deefield, IL,
USA). The transfection efficiency was determined as the
number of GFP-expressing cells divided by the total cell
number counted × 100.
The transfected cells were treated with LPS (1 μg/ml) and dif-
ferent concentrations (2.5, 5 and 10 μg/ml) of thiacremonone
for eight hours. Luciferase activity was measured by using the
luciferase assay kit (Promega, Madison, WI, USA), and read-
ing the results on a luminometer as described by the manufac-
turer's specifications (WinGlow, Bad Wildbad, Germany).
Western blot analysis
Western blot analysis was performed as described previously
[15]. The membrane was incubated for five hours at room tem-
perature with specific antibodies: mouse polyclonal antibodies
against p50 and p-IκB (1:500 dilution, Santa Cruz Biotechnol-
ogy Inc. Santa Cruz, CA, USA), rabbit polyclonal for p65 and
IκB (1:500 dilution, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and iNOS and COX-2 (1:1000 dilution, Cay-
man Chemical, Ann Arbor, MI, USA). The blot was then incu-
bated with the corresponding conjugated anti-mouse
immunoglobulin G-horseradish peroxidase (1:4,000 dilution,
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Immu-
noreactive proteins were detected with the enhanced chemi-
luminescence (ECL) western blotting detection system (GE
Healthcare Biosciences (formerly Amersham Biosciences),
Little Chalfont, Buckinghamshire, UK). The relative density of
the protein bands was scanned by densitometry using MyIm-
age (SLB, Seoul, Korea), and quantified by Labworks 4.0 soft-
ware (UVP Inc., Upland, CA, USA).
Assay of 12-O-tetradecanoylphorbol-13-acetate-induced 
ear edema in mice
The male Institute of Cancer Research (ICR) mice and male
Sprague-Dawley (SD) rats used here were maintained in
accordance with the National Institute of Toxicological
Research of the Korea Food and Drug Administration guide-
lines for the care and use of laboratory animals. The protocol
was approved by the Institutional Animal Care and Use Com-
mittee at Chungbuk National University. 12-O-tetradecanoyl-
phorbol-13-acetate (TPA; 1 μg/ear) alone or in combinationArthritis Research & Therapy    Vol 11 No 5    Ban et al.
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with thiacremonone (1 or 2 μg/ear) in acetone (10 μl) was
applied to the right ear of ICR mice. Control mice received
acetone alone. A volume (10 μL) of thiacremonone (1 or 2 μg/
ear) containing acetone was delivered to both the inner and
outer surfaces of the ear 30 minutes after TPA application.
After 24 hours, the tip of the ear thickness was measured
using vernier calipers (Mitutoyo Corporation, Kawasaki,
Japan), and ear punch biopsies 6 mm in diameter were taken
and weighed. Following this, the mice were sacrificed by cer-
vical dislocation. The increase in thickness or weight of the ear
punches was directly proportional to the degree of inflamma-
tion [38]. We further investigated the expression of iNOS and
COX-2 by western blot analysis, and the activation of NF-κB
by EMSA in each ear punch biopsies.
Carrageenan-induced paw edema inflammatory model 
and Mycobacterium butyricum-induced arthritis model
The anti-inflammatory and anti-arthritic property of thiacre-
monone was tested in male SD rats using the carrageenan
paw edema test according to the method of Sugishita and
colleagues [39] and a Mycobacterium butyricum-induced
arthritic model as described elsewhere [27]. Thiacremonone
(1 or 2 mg/kg), indomethacin (positive control, 10 mg/kg) or
vehicle (saline) was administered directly into the plantar sur-
face of the right hind paw 30 minutes after injection of carra-
geenan (0.05 ml; 3%, w/v in saline) into the subplantar area of
the right hind paw. The volumes of the injected and contralat-
eral paws were measured at one, two, three, and four hours
after induction of edema using a plethysmometer (Letica,
Comella, Spain). We next investigated the antiarthritic effect of
thiacremonone in a chronic adjuvant-induced arthritis (AIA)
animal model. AIA was elicited in SD rats by the injection of
0.1 ml of M. butyricum (10 mg/ml) in saline, into the subplantar
area of the right hind paw. Paw volumes were measured at the
beginning of the experiment using a water-displacement
plethysmometer. Animals with edema values of 1.1 ml larger
than normal paws were then randomized into treatment
groups. A 10 mg/kg dose of thiacremonone, indomethacin
(positive control) or vehicle (saline) was subcutaneously
administered into the plantar surface of the right hind paw from
day 1 to day 20 post AIA induction. The magnitude of the
inflammatory response was evaluated by measuring the vol-
umes of both hind paws. On day 21 post AIA induction, rats
under anesthesia were placed on a radiographic box at a dis-
tance of 90 cm from an x-ray source. Radiographic analysis of
arthritic hind paws was performed using an x-ray machine
(BLD-150RK, Hradec Králové, Czech Republic) with a 40 KW
exposition for 0.01 seconds. Paws were oriented horizontally,
relative to the detector. Radiographs were scored by an inves-
tigator who was blinded to the treatment information, using the
following scale: 0 = no bone damage, 1 = tissue swelling and
edema, 2 = joint erosion, and 3 = bone erosion and osteo-
phyte formation.
Data analysis
Data were analyzed using one-way analysis of variance fol-
lowed by Tuckey test as a post hoc test. Differences were con-
sidered significant at P < 0.05.
Results
Inhibitory effect of thiacremonone on TPA-induced ear 
edema in mice
Thiacremonone was evaluated for its anti-inflammatory activity
against TPA-induced edema formation and inflammatory gene
expression as well as NF-κB activity in mice. Topical applica-
tion of 1 μg TPA in acetone to the ear of a mouse increased
the average weight of the ear from 4.3 mg to 7.2 mg at 24
hours post application (Figure 2a). Topical application of 1 or
2 μg thiacremonone together with 1 μg TPA to the ears of
mice inhibited the TPA-induced edema of mouse ears by 44 or
98%, respectively (Figure 2a). We further investigated the
effect of thiacremonone on iNOS and COX-2 expression and
NF-κB activity in each ear punch biopsies by western blot
analysis and EMSA. Thiacremonone dose-dependently inhib-
ited TPA-induced expression of iNOS and COX-2 (Figure 2b).
Thiacremonone also inhibited TPA-induced NF-κB DNA-bind-
ing activity (Figure 2c) as well as the nuclear translocation of
p50 and p65 and phosphorylation of IκBα (Figure 2d).
Inhibitory effect of thiacremonone on carrageenan and 
adjuvant-induced arthritis
The anti-inflammatory activity of thiacremonone was also dem-
onstrated in the carrageenan paw edema test in SD rats.
Direct administration of thiacremonone (1 or 2 mg/kg) into the
plantar surface of the right hind paw 30 minutes before injec-
tion of carrageenan (0.05 ml; 3%, w/v in saline into the sub-
plantar area of the right hind paw, 1.5 mg/paw) showed greatly
reduced carrageenan-induced paw edema (40% reduction
compared to contralateral paws; Figure 3a). A dose-depend-
ent inhibition of the expression of iNOS and COX-2 (Figure
3b) as well as the activation of NF-κB DNA-binding activity
(Figure 3c) accompanied by an inhibition of p50 and p65
nuclear translocation and phosphorylation of IκBα (Figure 3d)
was also reported. In a chronic rat AIA model, oral administra-
tion of thiacremonone (5 or 10 mg/kg) for 20 days significantly
reduced adjuvant-induced hind paw edema formation (Figure
4a). A radiographic examination of hind paws revealed tissue
swelling at the paw of adjuvant-injected rats. However, these
effects were markedly reduced by thiacremonone treatment,
and its inhibitory effect was comparable with indomethacin
(10 mg/kg; Figure 4b). Treatment with thiacremonone did not
affect progression of body weight, and did not show any
behavioral alternation (data not shown), suggesting that thia-
cremonone itself (10 mg/kg) did not cause any toxic response.
Thiacremonone dose-dependently inhibited the expression of
iNOS and COX-2 (Figure 4c). It also suppressed the activa-
tion of NF-κB DNA-binding activity (Figure 4d) as well as the
nuclear translocation of p50 and p65 and phosphorylation of
IκBα (Figure 4e).Available online http://arthritis-research.com/content/11/5/R145
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Effect of thiacremonone on NF-κB-luciferase activity and 
NF-κB DNA binding activity
To test whether thiacremonone was able to attenuate NF-κB-
mediated promoter activity, we used a luciferase reporter gene
expressed under the control five κB cis-acting elements. RAW
264.7 cells were transiently transfected with an NF-κB-
dependent luciferase reporter construct according to the man-
ufacturef's specifications (Promega, Madison, WI, USA). The
cells were then treated with LPS (1 μg/ml) or co-treated with
LPS and thiacremonone for six hours. Treatment of cells with
thiacremonone resulted in a concentration-dependent sup-
pression of luciferase activity induced by LPS (Figure 5a). To
determine whether thiacremonone was also able to inhibit the
DNA-binding activity of NF-κB in RAW 264.7 cells, nuclear
extracts from co-treated cells were prepared and assayed for
NF-κB DNA-binding activity by EMSA. LPS induced a strong
NF-κB DNA-binding activity that was attenuated by co-treat-
ment of the cells with thiacremonone in a dose-dependent
manner (Figure 5b).
Treatment of cells with LPS (1 μg/ml) increased the nuclear
translocation of NF-κB subunits p65 and p50. However, in the
presence of thiacremonone, nuclear translocation of p50 and
p65 was inhibited in a dose-dependent manner (Figure 4c).
Thiacremonone also inhibited LPS-induced degradation of
IκB-α (increase phosphorylation) in RAW 264.7 cells (Figure
5c). We also found that exposure of RAW 264.7 cells to thia-
cremonone for one hour inhibited the DNA-binding activity of
NF-κB that was induced by TNF-α (10 ng/ml), IL-1α (10 ng/
ml) and interferon-γ (IFN-γ; 10 ng/ml; Figure 5d). The dose-
Figure 2
Effects of thiacremonone on TPA-induced ear edema, and expression of iNOS and COX-2 in mice Effects of thiacremonone on TPA-induced ear edema, and expression of iNOS and COX-2 in mice.  (a) 12-O-tetradecanoylphorbol-13-acetate 
(TPA; 1 μg/ear) alone or together with thiacremonone (Thia; 1 or 2 μg/ear) in 10 μl acetone was topically applied to the right ear of Institute of Can-
cer Research (ICR) mice (n = 6). The thickness or weight of the ear punches were determined as described in Materials and Methods. (b) Equal 
amounts of total proteins (40 μg/lane) were subjected to 10% SDS-PAGE, and the expression of inducible nitric oxide synthetase (iNOS) and 
cyclooxygenase-2 (COX-2) in mice ear edema tissues (2 lanes/each group) was detected by western blotting using specific antibodies. β-actin pro-
tein was used as an internal control. (c) DNA-binding activity of nuclear factor (NF)-κB was determined by electromobility shift assay (EMSA) in 
nuclear extracts from mice ear edema tissues (2 lanes/each group) as described in Materials and Methods. (d) Equal amounts of total proteins (40 
μg/lane) were subjected to 10% SDS-PAGE, and nuclear translocation of p50 and p65, and degradation of inhibitory (I) κB in mice ear edema tis-
sues (2 lanes/each group) was detected by western blotting using specific antibodies. β-actin protein was used as an internal control. Values are 
mean ± standard deviation (n = 6). # indicates significantly different from control group (P < 0.05). * P < 0.05 indicate statistically significant differ-
ences from the TPA-treated group.Arthritis Research & Therapy    Vol 11 No 5    Ban et al.
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dependent inhibitory effect of thiacremonone on LPS-induced
DNA binding activity of NF-κB was also seen in THP-1 cells
(Figure 5e). This DNA-binding activity of NF-κB was confirmed
by competition assays as well as by super shift assays. In the
presence of a p50 antibody, the DNA-binding activities of NF-
κB showed a super shift. However, in the presence of a p65
antibody, the DNA-binding activity of NF-κB was decreased
without a super shift, suggesting that p50 might be a target of
thiacremonone, interfering with the DNA-binding activity of
NF-κB (Figure 5c).
Effect of thiacremonone on LPS-induced NO production 
as well as expression of iNOS and COX-2 in RAW 264.7 
cells
The effect of thiacremonone (2.5, 5, 10 μg/ml) on LPS-
induced NO production in RAW 264.7 cells was investigated
by measuring the accumulated nitrite, as estimated by Griess
reaction, in the culture medium. After co-treatment with LPS
and thiacremonone for 24 hours, LPS-induced nitrite concen-
tration in the medium was decreased remarkably in a concen-
tration-dependent manner. The IC50 value of thiacremonone in
inhibiting LPS-induced NO production was 8 μM (Figure 6a).
To investigate whether the inhibitory effect of thiacremonone
affected NO production via inhibition of corresponding gene
Figure 3
Effect of thiacremonone on carrageenan-induced arthritis in rats Effect of thiacremonone on carrageenan-induced arthritis in rats.  (a) Thiacremonone (Thia; 1 and 2 mg/kg) or indomethacin (Indo; 10 mg/kg) or 
vehicle (saline) was orally administered 30 minutes before carrageenan (0.05 ml; 3%, w/v in saline) into the planter area of the right hind paw of rat 
(n = 10). The volumes of the injected paws were monitored for four hours in 10 rats per each group as described in Materials and Methods. (b) 
Equal amounts of total proteins (40 μg/lane) were subjected to 10% SDS-PAGE, and the expression of inducible nitric oxide synthetase (iNOS) and 
cyclooxygenase-2 (COX-2) in rat paw arthritis tissues was detected by western blotting using specific antibodies. β-actin protein was used as an 
internal control. (c) DNA-binding activity of nuclear factor (NF)-κB was determined by electromobility shift assay (EMSA) in nuclear extracts from 
mice paw arthritis tissues (3 lanes/each group) as described in Materials and Methods. (d) Equal amounts of total proteins (40 μg/lane) were sub-
jected to 10% SDS-PAGE, and nuclear translocation of p50 and p65, and degradation of inhibitory (I) κB in rat paw arthritis tissues was detected 
by western blotting using specific antibodies. β-actin protein was used as an internal control. Values are mean ± standard deviation (n = 10). # indi-
cates significantly different from control group (P < 0.05). * P < 0.05 indicate statistically significant differences from the carrageenan-treated group.Available online http://arthritis-research.com/content/11/5/R145
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expression, iNOS luciferase activity and expression of iNOS
and COX-2 was determined. Transcriptional regulation of
iNOS expression by thiacremonone was determined in RAW
264.7 transfected with iNOS-luciferase construct containing
murine iNOS promoter (-1592/+183) fused to luciferase gene
as a reporter [39]. Thiacremonone inhibited LPS-induced
iNOS luciferase activity in a concentration-dependent manner
(Figure 6b). Upon LPS treatment for 24 hours, iNOS expres-
sion was also significantly increased in RAW 264.7 cells, and
co-treatment of cells with LPS and different concentration of
thiacremonone decreased LPS-induced iNOS expression in a
concentration-dependent manner (Figure 6c). In agreement
with the inhibitory effect on NO generation, the densitometry
data showed that the iNOS expression was inhibited by thia-
cremonone in a concentration-dependent manner. As NO can
induce COX-2 expression, and COX-2 is also an enzyme to
regulate inflammation, the expression of COX-2 was investi-
gated. Consistent with the inhibitory effect on iNOS expres-
sion, thiacremonone inhibited LPS-induced COX-2
expression, but the extent was much less than on iNOS (Fig-
ure 6c).
Figure 4
Effect of thiacremonone on adjuvant-induced arthritis in rats Effect of thiacremonone on adjuvant-induced arthritis in rats.  (a) Thiacremonone (Thia; 10 mg/kg) and indomethacin (Indo; 10 mg/kg) were orally 
administered for 20 days after injection of adjuvant into the plantar surface of right hind paw of 10 rats per group. Hind paw volume and clinical 
score were determined for 20 days as described in Materials and Methods. (b) A radiographic examination of hind paws revealed tissue swelling at 
the paw after 20 days. The clinical value was determined in 10 rats as described in Materials and Methods. (c) Equal amounts of total proteins (40 
μg/lane) were subjected to 10% SDS-PAGE, and the expression of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) in rat 
paw arthritis tissues (3 lanes/each group) was detected by western blotting using specific antibodies. β-actin protein was used as an internal con-
trol. (d) DNA-binding activity of nuclear factor (NF)-κB was determined by electromobility shift assay (EMSA) in nucleus extract from rat paw arthritis 
tissues (3 lanes/each group) as described in Materials and Methods. (e) Equal amounts of total proteins (40 μg/lane) were subjected to 10% SDS-
PAGE, and nuclear translocation of p50 and p65, and degradation of inhibitory (I) κB in rat paw arthritis tissues was detected by western blotting 
using specific antibodies. β-actin protein was used as an internal control. Values are mean ± standard deviation (n = 10). # indicates significantly dif-
ferent from control group (P < 0.05). * indicates significantly different from the Mycobacterium butyricum-treated group (P < 0.05).Arthritis Research & Therapy    Vol 11 No 5    Ban et al.
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To disprove the inhibitory effect of thiacremonone on NO pro-
duction via inhibition of cell growth, the cytotoxic effect of thi-
acremonone was evaluated in the absence or presence of LPS
in the RAW 264.7 cells by CCK-8 assay. Thiacremonone (up
to 10 μg/ml) did not affect the cell viability in the absence of
LPS (data not shown) or the presence of LPS in RAW 264.7
cells (Figure 6d). Therefore, thiacremonone inhibited LPS-
induced NO production in RAW 264.7 cells without any toxic
effect.
Suppression of thiacremonone-induced inhibition of 
DNA binding activity of NF-κB and cell growth by thiol 
reducing agents, and in the cells transfected with mutant 
p50
We further tested whether the inhibition of NF-κB was due to
an interaction between the sulfhydryl group of the p50 subunit
of NF-κB and thiacremonone, as previously seen in colon can-
cer cells [15]. Cells were co-treated with thiacremonone and
reducing agents, dithiothreitol (DTT) or glutathione for one
Figure 5
Effect of thiacremonone on LPS-induced NF-κB activation in RAW 264.7 and THP-1 cells Effect of thiacremonone on LPS-induced NF-κB activation in RAW 264.7 and THP-1 cells.  (a) RAW 264.7 cells were transfected with p-NF-κB-
Luc plasmid (5× nuclear factor (NF)-κB), and then treated with lipopolysaccharide (LPS; 1 μg/ml) alone or in combination with thiacremonone (Thia; 
2.5, 5, 10 μg/ml) at 37°C for six hours. Luciferase activity was then determined as described in Materials and Methods. (b) The DNA-binding activity 
of NF-κB was investigated using electromobility shift assay (EMSA) as described in Materials and Methods. Nuclear extracts from RAW 264.7 cells 
with LPS alone (1 μg/mL) or in combination with thiacremonone (2.5, 5, 10 μg/ml) were subjected to DNA-binding reactions with 32P end-labeled 
oligonucleotide specific to NF-κB. The specific DNA-binding activity of NF-κB complex is indicated by an arrow. (c) For competition assays, nuclear 
extracts from RAW 264.7 cells treated with LPS (1 μg/ml) were incubated for one hour before EMSA with unlabeled NF-κB oligonucleotide or 
labeled NF-κB oligonucleotide. For supershift assays, nuclear extracts from RAW 264.7 cells treated with LPS (1 μg/ml) were incubated for one 
hour before EMSA with specific antibodies against the p50 and p65 NF-κB isoforms. SS indicates supershift band. (d) Cells treated with 1 μg/mL 
of LPS only or LPS plus different concentrations (2.5, 5, 10 μg/ml) of thiacremonone at 37°C for one hour. Equal amounts of total protein (40 μg) 
were subjected to 10% SDS-PAGE. Nuclear translocation of p50 and p65, and degradation of inhibitory (I) κB were detected by western blotting 
using specific antibodies. β-actin protein was used as an internal control. (e) Nuclear extracts from RAW 264.7 cells with another inducer alone 
(TNF-α (10 ng/ml), IL-1α (10 ng/ml), IFN-γ (10 ng/ml)) or in combination with thiacremonone (10 μg/ml) were subjected to DNA-binding reactions 
with 32P end-labeled oligonucleotide specific to NF-κB. The specific DNA-binding of NF-κB complex is indicated by an arrow. (f) Nuclear extracts 
from THP-1 cells with LPS alone (1 μg/mL) or in combination with thiacremonone (2.5, 5, 10 μg/ml) were subjected to DNA-binding reactions with 
32P end-labeled oligonucleotide specific to NF-κB. The specific DNA-binding of NF-κB complex is indicated by an arrow. Values (A, B and C) are 
mean ± standard deviation of three independent experiments performed in triplicate. # indicates significantly different from control group (P < 0.05). 
* indicates significantly different from the LPS-treated group (P < 0.05).Available online http://arthritis-research.com/content/11/5/R145
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hour, and then the DNA-binding activity of NF-κB was exam-
ined. We found that these reducing agents significantly sup-
pressed the inhibitory effects of thiacremonone on the DNA-
binding and transcriptional activity of NF-κB (Figures 7a, b).
Furthermore, DTT and glutathione suppressed the inhibitory
effects of thiacremonone on NO generation (Figure 7c) and
iNOS luciferase activity (Figure 7d).
Taking into consideration the supershift of the DNA-binding
activities of NF-κB upon addition of anti-p50 antibody, and the
suppressive effect of DTT and glutathione on thiacremonone-
induced inhibition of DNA-binding activity of NF-κB and NO
generation, we postulated that the sulfhydryl residue in p50
might be a target of thiacremonone. To test this postulation,
we further studied the inhibitory effects of thiacremonone on
the DNA-binding activity of NF-κB and NO generation in p50
mutant cells (C62S), where the cysteine residue at 62 of p50
was replaced by serine. As expected, there was a reduction in
the inhibitory effect of thiacremonone on the DNA-binding
activity of NF-κB (Figure 7e) and on NO generation (Figure 7f)
Figure 6
Effect of thiacremonone on LPS-induced NO generation, expression of iNOS and COX-2 and cell viability in RAW 264.7 cells Effect of thiacremonone on LPS-induced NO generation, expression of iNOS and COX-2 and cell viability in RAW 264.7 cells.  (a) The cells were 
treated with 1 μg/mL of lipopolysaccharide (LPS) only or LPS combined with different concentrations (2.5, 5, 10 μg/ml) of thiacremonone (Thia) at 
37°C for 24 hours. Nitric oxide (NO) generation was determined in culture medium as described in Materials and Methods. (b) The cells were tran-
siently transfected with an inducible nitric oxide synthetase (iNOS)-luciferase construct, and activated with LPS (1 μg/ml) alone or LPS combined 
with the indicated concentrations of thiacremonone for eight hours. Luciferase activity was then determined. Quantification of band intensities from 
three independent experimental results was determined by a densitometry, and the value under the band indicate fold difference (average) from 
untreated control group. (c) The cells were treated with 1 μg/mL of LPS only or LPS combined with different concentrations (2.5, 5, 10 μg/ml) of thi-
acremonone at 37°C for 24 hours. Equal amounts of total proteins (40 μg/lane) were subjected to 10% SDS-PAGE, and the expression of iNOS 
and COX-2 was detected by western blotting using specific antibodies. β-actin protein was used as an internal control. (d) RAW 264.7 cells were 
treated with various doses (2.5, 5, 10 μg/ml) of thiacremonone for 24 hours. Morphological changes were observed under microscope (magnifica-
tion, ×200). Cell viability was determined by the CCK-8 assay described in Materials and Methods. Cells were incubated with thiacremonone in the 
absence or presence of LPS. Results were given in percentage related to untreated controls. All values (A, B, C and D) represent the means ± 
standard deviation of three independent experiments performed in triplicate. # indicates significantly different from control group (P < 0.05). * indi-
cates significantly different from the LPS-treated group (P < 0.05).Arthritis Research & Therapy    Vol 11 No 5    Ban et al.
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in these p50 mutant cells. These results clearly suggested that
thiacremonone mediated its effects through modulation of
cysteine residues of the p50 subunit of NF-κB.
Discussion
The activation of iNOS catalyzes the formation of a large
amount of NO, which plays a key role in the pathogenesis of a
variety of inflammatory diseases [40-43]. Activation of NF-κB
is critical in the induction of iNOS [44-46]. Therefore, agents
that inhibit NF-κB, resulting in decreased iNOS expression
and NO generation, may have beneficial therapeutic effects in
the treatment of inflammatory diseases. Thiacremonone inhib-
ited LPS-induced iNOS and COX-2 expression accompanied
by a reduction in NO generation. Consistent with its inhibitory
activity on NO production, thiacremonone also decreased NF-
κB activity. The inhibitory effects of thiacremonone on the NF-
κB DNA-binding activities were also demonstrated in macro-
phages stimulated by TNF-α, IFN-γ, and IL-1α. The promoter
of the iNOS gene contains two major discrete regions syner-
gistically functioning toward the binding of transcription factor
NF-κB, which is mainly activated by LPS and IFN-γ, and IL-1α
[47,48]. Therefore, these data indicated that thiacremonone
could interfere with NF-κB-mediated signals involving the pro-
duction of pro-inflammatory molecule NO, and thus give anti-
inflammatory responses.
In vivo animal studies showed that thiacremonone inhibited
TPA, carrageenan and M. butyricum-induced paw edema.
Treatment of thiacremonone also resulted in a great reduction
of tissue swelling and osteophyte formation in a chronic arthri-
tis rat model. Paralleled with these inhibitory effects, thiacre-
monone also inhibited TPA, carrageenan and M. butyricum-
Figure 7
Abolition of the inhibitory effect of thiacremonone by DTT and glutathione GSH, and in the cells harboring mutant p50 on NO generation and DNA  binding activation of NF-κB Abolition of the inhibitory effect of thiacremonone by DTT and glutathione GSH, and in the cells harboring mutant p50 on NO generation and DNA 
binding activation of NF-κB.  (a) RAW 264.7 cells grown in six-well plates were cotreated with indicated concentrations of dithiothreitol (DTT) (100 
nM) or glutathione (GSH; 100 μM) with thiacremonone (Thia; 10 μg/ml) for one hour. Nuclear extracts were then prepared and examined by electro-
mobility shift assay (EMSA) as described in Materials and Methods. (b) The cells were transiently transfected with nuclear factor (NF)-κB-luciferase 
construct, and were co-treated with indicated concentrations of DTT (1 to 100 nM) or GSH (1 to 100 μM) with thiacremonone (10 μg/ml) for eight 
hours, and then the luciferase activity was determined. (c) The cells were co-treated with indicated concentrations of DTT (1 to 100 nM) or GSH (1 
to 100 μM) with 1 μg/mL of lipopolysaccharide (LPS) only or LPS plus thiacremonone (10 μg/ml) at 37°C for 24 hours. Nitric oxide (NO) generation 
was determined in culture medium as described in Materials and Methods. (d) The cells were transiently transfected with inducible nitric oxide syn-
thetase (iNOS)-luciferase construct, and were co-treated with indicated concentrations of DTT (1 to 100 nM) or GHS (1 to 100 μM) with thiacre-
monone (10 μg/ml) for eight hours, and then the luciferase activity was determined. (e) RAW 264.7 cells were transfected with p50 mutant (C62S) 
plasmid at 37°C for six hours, and then NF-κB DNA-binding activity was determined after one hour of treatment with thiacremonone by electromobil-
ity shift assay (EMSA) as described in Materials and Methods. (f) NO generation was determined in culture medium as described in Materials and 
Methods. RAW 264.7 cells were transfected with p50 mutant (C62S) plasmid at 37°C for six hours, and then NO generation was determined after 
24 hours treatment with thiacremonone as described in Materials and Methods. All values represent the means ± standard deviation of three inde-
pendent experiments performed in triplicate. # indicates significantly different from control group (P < 0.05). * P < 0.05 indicate statistically signifi-
cant differences from the LPS-treated group.Available online http://arthritis-research.com/content/11/5/R145
Page 11 of 13
(page number not for citation purposes)
induced iNOS and COX-2 expression, as well as NF-κB activ-
ity in vivo. Thiacremonone inhibited the production of TNF-α
as well as the expression of matrix metalloproteinases (MMP-
3 and 9) and chemokines in these tissues (data not shown).
Activation of the NF-κB pathway results in the transactivation
of a multitude of responsive genes that contribute toward the
inflammatory phenotype, including TNF-α from macrophages,
MMPs from synovial fibroblasts and chemokines that recruit
immune cells to the inflamed pannus. This is largely a conse-
quence of the activation of the NF-κB pathway that involves
homodimers and heterodimers of p50/p65 [49]. We thus
speculated that the in vivo effects of thiacremonone on
arthritic models were mediated by its combined inhibitory
actions on multiple responses of synovial cells and inflamma-
tory cells through the inactivation of NF-κB. Interestingly; we
also found that thiacremonone inhibited NF-κB and iNOS
expression in cultured THP-1 monocytes. In light of these data,
the results of our study indicate that inhibition of NF-κB by thi-
acremonone could be beneficial for the treatment of inflamma-
tory diseases such as arthritis.
The inhibition of NF-κB activation by thiacremonone was
found to be suppressed by treatment of cells with reducing
agents such as DTT and glutathione. This was accompanied
by a suppression of the inhibitory effect of thiacremonone on
NO generation. Thus, it is possible that the inhibitory effects of
thiacremonone on NF-κB activity may be mediated by oxidiz-
ing the critical cysteine residue present in NF-κB subunits. We
also found that in the presence of an antibody against p50 but
not p65, the NF-κB DNA-binding activity was supershifted.
Further evidence showed that the inhibitory effect of NO gen-
eration and NF-κB activity by thiacremonone in p50 mutant
(cysteine was replaced with alanine) cells was suppressed. It
is noteworthy that p50/p50 homodimer is more important than
p50/p65 heterodimers in the regulation of inflammatory
cytokine generation and inflammatory diseases. It was found
that increased cytokine levels in p50 knockout mice may be
related to the different transcriptional activity of p50/p50
homodimer rather than p65/p50 heterodimer or p65/p65
homodimer [50]. Targeted disruption of the p50 subunit of NF-
κB reduces atherosclerotic lesions with an inflammatory phe-
notype as well as ventricular rupture after myocardial infarc-
tion, a proinflammatory disease [51,52]. These results suggest
that p50/p50 may be more important to relay inflammatory
gene expression than that of p65/p50 or p65/65 in the inflam-
matory responses. Therefore, there studies support the possi-
bility that the sulfhydryl residue of p50 may be a target of
thiacremonone in the present study. Previous our study dem-
onstrated that thiacremonone inhibited cancer cell growth
through inhibition of NF-κB, and may be p65 is the target of
thiacremonone [15]. Contrast to the inflammatory response, in
the cancer cells, p65 may be important in the activation of NF-
κB, and many of anti-cancer drugs target p65 of NF-κB. Our
data in the cancer cell study is consistent with those previously
reported from other laboratory with caffeic acid phenethyl
ester [53] and sesquiterpene lactone parthenolide [54]. Sev-
eral other investigators demonstrated that sulfur compounds
react with cysteine residues of target molecules in intracellular
signal transduction proteins including NF-κB through
cysteine-cysteine interaction or other binding ways, and thus
inhibit inflammatory responses and development of arthritic
rheumatism [14,31,32]. We recently also demonstrated that
2-hydroxycinnamaldehyde, a snake venom toxin and melittin
inhibit inflammatory responses and cancer cell growth through
modification of sulfhydryl residues of NF-κB and regulatory
proteins (p50 and p65 as well as IκB kinases (IKKs))
[27,28,55]. Therefore, the inhibition of NF-κB activation by thi-
acremonone through direct modification of p50 may be an
important molecular mechanism of the suppressive effect of
thiacremonone on inflammatory responses and arthritic reac-
tions. However, in our present study, thiacremonone inhibited
both the expression of IκB as well as its phosphorylation, but
the extent of the inhibition of phosphorylation was much
greater than the inhibition of IκB expression. Thus, these
results could give possibilities that thiacremonone can sup-
press the expression of IκB and p-IκB as well as inhibit phos-
phorylation. As the sulfhydryl group of IKKs are also important
in the activity of IKKs as well as NF-κB, thiacremonone could
be effective in the regulation of IKKs. We are currently investi-
gating these issues.
The effective dose of thiacremonone (10 mg/kg) used in this
chronic AIA study was comparable with that of the classic anti-
inflammatory drug indomethacin. We did not detect any side
effects of thiacremonone (loss of weight gain and any
observed toxic signs) during treatment for 20 days. Taken
together, thiacremonone, a novel sulfur compound isolated
from garlic inhibited iNOS expression and NO generation
through prevention of NF-κB activity in vitro, and ameliorated
inflammatory responses and arthritic reactions in acute and
chronic edema and arthritic animal models. These data
suggest that thiacremonone may be potentially beneficial for
the prevention of inflammatory diseases such as arthritic rheu-
matism with comparatively low toxic effects.
Conclusions
Our results indicate that thiacremonone suppressed the TPA-
induced ear edema, and carrageenan and M. butyricum-
induced arthritis through inhibition of NF-κB DNA-binding
activity and expression of iNOS and COX-2. In in vitro studies
using Raw 264.7 and THP-1 cells, thiacremonone also inhib-
ited LPS-induced NO production, NF-κB activity and expres-
sion of iNOS and COX-2, which are classical markers of
inflammation. These inhibitory effects were suppressed by
reducing agents such as DTT and glutathione, and were abro-
gated in the cells expressing p50 (C62S) mutant. Therefore,
we conclude that thiacremonone exerted its anti-inflammatory
and anti-arthritic properties through the inhibition of NF-κB
activation via interaction with the sulfhydryl group of NF-κB
molecules.Arthritis Research & Therapy    Vol 11 No 5    Ban et al.
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